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Abstracts AB125398 The clinically important impact of preschoolfood oral immunotherapy on parental quality of
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RATIONALE: Our group previously showed the safety of peanut oral
immunotherapy (OIT) in 270 preschool-aged children (0.4% had severe
reactions). The impact of preschool OIT on parental quality of life (QoL)
has not been previously described.
METHODS: We enrolled preschool-aged children into OIT. The project
was conducted in four clinics across Canada (Halifax, Winnipeg,
Edmonton, Vancouver). The OIT protocol used capsules and/or food,
and the maintenance dose was 300mg of protein daily. The 17-item Food
Allergy Quality of Life– Parental Burden (FAQL-PB) questionnaire was
administered to parents at baseline and end of build-up, and Wilcoxon
signed-rank test was performed to compare the FAQL-PB scores between
timepoints.
RESULTS: Between May/2019-August/2020, 29 patients aged 9–32.3
months (58.6% males) completed OIT (28 peanut, 1 sesame), and FAQL-
PB questionnaires. Therewas a significant improvement in FAQL-PB from
baseline to end of build-up with a median change in score of -14 ((IQR:
-33.5, -7.5); p<0.00001), representing a change of 0.82 in mean total score
(>_0.5 is considered a minimal clinically important difference [MCID]).
CONCLUSIONS: Our real-world study found that preschool OIT
improves parent QoL from baseline to end of build-up (exceeding the
MCID), even though families may be most fearful of potential reactions
during this period based on reaction risks described in older children. This
reduction in parental burden is most likely associated with the superior
safety experienced by families of preschoolers. Future work will involve
analyzing QoL at various timepoints during maintenance, to determine
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RATIONALE: To report the efficacy of 4-weekly add-on mepolizumab
100 mg SC on health-related quality of life (HRQoL) in adults with
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) .
METHODS: SYNAPSE (NCT03085797), a randomised, double-blind,
placebo-controlled, multicentre, 52-week study, enrolled adult patients
with highly symptomatic CRSwNP and prior surgery, treated with
intranasal corticosteroids. Co-primary endpoints: change from baseline
in endoscopic NP score (Week 52) and nasal obstruction visual analogue
scale (VAS) score (Weeks 49–52). HRQoL was measured every 4 weeks
using the SinoNasal Outcome Test (SNOT-22), assessing symptoms and
impact of CRSwNP. Blinded psychometric analysis of SYNAPSE data and
prior qualitative research in patients with CRSwNP was conducted to
confirm domain structure and meaningful within-patient change
thresholds.
RESULTS: Psychometric analyses support a six-domain solution: nasal
symptoms, ear/facial symptoms, non-nasal symptoms, fatigue, impact on
sleep, and emotional impact supporting the validity of a total score. A
threshold of -28 points was defined using anchor-based methods and
supported by distribution-based methods. Although substantially greater
than previously published thresholds, this value is supported by qualitative
patient research. LS mean change from baseline total score at week 52 was
-29.5 (SE1.62) for mepolizumab and -15.6 (SE 1.65) for placebo, with 54%
and 32% responders respectively (post-hoc analyses). Odds ratio of
response was 2.66 95% CI (1.75, 4.04) favouring mepolizumab. Change
from baseline in all domain scores was approximately twice as large for
mepolizumab compared with placebo, with similar magnitude of improve-
ment across all domains.
CONCLUSIONS: Mepolizumab significantly and meaningfully im-
proves HRQoL in CRSwNP.
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